In addition, glucagon‐like peptide‐1 (GLP‐1) receptor agonists can reduce the risk of major cardiovascular events in cancer patients treated with ICIs (with a median follow‐up of 12 months, the incidence of major adverse cardiovascular events was significantly lower than the control group) [274]. The gene discussed is GLP1R; the disease is cancer.